LMBA02 Protocol for Patients With a Burkitt Lymphoma

Status Recruiting

Clinical Trial Summary

To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Burkitt Lymphoma

Clinical Trial Details

NCT number	NCT00180882
Study type	Interventional
Source	Gustave Roussy, Cancer Campus, Grand Paris
Contact	Vincent RIBRAG, MD
Phone	33 1 42 11 43 47
Email	ribrag@igr.fr
Status	Recruiting
Phase	Phase 3
Start date	October 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01943682` - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma	Phase 1
Completed	`NCT01093586` - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Recruiting	`NCT05020392` - Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma	Phase 3
Recruiting	`NCT04545762` - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	Phase 1
Terminated	`NCT03864419` - Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda	Phase 1
Terminated	`NCT02700022` - A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas	Phase 1
Completed	`NCT00849147` - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)	Phase 2
Completed	`NCT00822432` - Coproporphyrine Isomers and Methotrexate Elimination	N/A
Recruiting	`NCT06060782` - Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine	Phase 1
Active, not recruiting	`NCT02996773` - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine	Phase 1
Recruiting	`NCT05565417` - Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Phase 1/Phase 2
Not yet recruiting	`NCT03298828` - CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma	Phase 1
Completed	`NCT01290120` - Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma	Phase 2
Active, not recruiting	`NCT00719888` - Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease	Phase 2
Recruiting	`NCT06131801` - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting	`NCT04425421` - Recommendations for the Treatment of Children With Burkitt's Lymphoma
Active, not recruiting	`NCT00001337` - Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma	Phase 2
Recruiting	`NCT05518383` - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021	Phase 4
Terminated	`NCT01028716` - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Recruiting	`NCT05794880` - MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	N/A